"Die III. Medizinische Klinik für Hämatologie und Onkologie am Universitätsklinikum Mannheim befasst sich mit der Diagnostik und Therapie sämtlicher Blut- und Krebserkrankungen bei Erwachsenen. Das moderne Behandlungsspektrum umfasst auch allogene Stammzelltransplantationen in einer der modernsten Stammzelltransplantationseinheiten Europas. Ein weiterer Schwerpunkt ist die umfassende Betreuung schwerstkranker Patienten in palliativer Situation."

During the past decade, III Medizinische Klinik Mannheim conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "III Medizinische Klinik Mannheim" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "German CLL Study Group" with 4 trials sponsored, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 4 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored and "Blueprint Medicines Corporation" with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "III Medizinische Klinik Mannheim" #1 collaborator was "Bayer Healthcare LTD" with 1 trials as a collaborator, "Celltrion Healthcare Co., LTD" with 1 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "German CLL Study Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "III Medizinische Klinik Mannheim" are "Leukemia" (5 trials), "Lymphoma" (4 trials), "Chronic Lymphocytic Leukemia" (3 trials), "Melanoma (Skin)" (3 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "III Medizinische Klinik Mannheim" in a lesser frequency.

Most popular intervention types in "III Medizinische Klinik Mannheim" are "Drug" (27 trials), "Biological" (11 trials), "Radiation" (6 trials), "Procedure" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (6 trials), "cyclophosphamide" (5 trials), "recombinant interferon alfa" (5 trials), "Placebo" (4 trials) and "Rituximab" (4 trials). Other intervention names were less common.

The vast majority of trials in "III Medizinische Klinik Mannheim" are 32 trials for "All" genders.

Currently, there are NaN active trials in "III Medizinische Klinik Mannheim". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in III Medizinische Klinik Mannheim, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in III Medizinische Klinik Mannheim, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".